Insmed Raises FY26 Revenue Outlook For BRINSUPRI And ARIKAYCE, Stock Up In Pre-Market

Insmed (INSM) shares rose 15.1% on October 29, 2026, after reporting Q3 2026 results. Revenue of $524.4M beat estimates, but loss per share was wider. BRINSUPRI revenue grew 29% QoQ, and guidance was raised. R&D and sales costs increased 40% YoY. The stock is down 32.5% over the past year.

Goldman Sachs maintained a Buy rating and $194 price target for Insmed (INSM) after its quarterly results beat estimates. Brinsupri revenue was $400.1M, exceeding expectations. Insmed raised its 2026 guidance for Brinsupri to $1.35B-$1.40B. The stock rose 19.5% to $111.59. Analysts have revised earnings upwards, with price targets ranging from $165 to $243.

Insmed Inc (INSM) reported positive Q3 2026 earnings, with Brinsupri showing strong persistency and revenue trends. The company expects cash flow positivity in 2027 and provided updates on TPIP trials and Erakase's label expansion. Dr. Martina Flammer highlighted growth opportunities in comorbid COPD and asthma bronchiectasis, with data expected in mid-2027. Insmed also discussed AI use for patient identification and the potential impact of real-world studies.

Insmed (INSM) shares rose 12% after Q3 revenue of $524.4M, driven by $400.1M from Brinsupri, beating expectations. The company raised 2026 guidance for Brinsupri to $1.35B-$1.4B. Spending increased due to TPIP trials, a potential rival to United Therapeutics' Tyvaso. FDA decision on Arikayce label expansion is due Jan. 28, 2027.

Insmed (INSM) reported Q3 earnings, highlighting AI diagnostic tools for bronchiectasis, expected to share findings in 2027. FDA granted priority review for ARIKAYCE's sNDA, with a target action date of Jan. 28, 2027. The company expects cash-flow positivity in 2027. Insmed also provided updates on its pipeline, including TPIP and INS1033 programs. Cost of product revenues was $78.2 million, or 14.9% of revenue, with combined R&D and SG&A expenses up 40% year over year.

Insmed (INSM) reported Q3 2026 revenue of $400.1M for BRINSUPRI, up 29% sequentially. The company raised its 2026 revenue guidance to $1.35B-$1.4B. Insmed expects its lead respiratory assets to exceed $14B in peak sales, with BRINSUPRI potentially reaching $7B+ and TPIP $6B+.